Pfizer Given Average Rating of “Buy” by Analysts (NYSE:PFE)
Shares of Pfizer (NYSE:PFE) have been given an average recommendation of “Buy” by the eighteen analysts that are currently covering the stock, Analyst Ratings.Net reports. Seven analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $33.54.
Pfizer (NYSE:PFE) opened at 29.49 on Thursday. Pfizer has a 52-week low of $27.81 and a 52-week high of $32.96. The stock’s 50-day moving average is $29.3 and its 200-day moving average is $30.35. The company has a market cap of $187.0 billion and a P/E ratio of 18.52. Pfizer also was the target of a significant drop in short interest in August. As of August 15th, there was short interest totalling 69,502,226 shares, a drop of 4.3% from the July 31st total of 72,619,112 shares. Based on an average daily trading volume, of 24,441,395 shares, the days-to-cover ratio is presently 2.8 days. Currently, 1.1% of the shares of the company are sold short.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 29th. The company reported $0.58 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.57 by $0.01. The company had revenue of $12.80 billion for the quarter, compared to the consensus estimate of $12.49 billion. During the same quarter last year, the company posted $0.56 earnings per share. Pfizer’s revenue was down 1.5% compared to the same quarter last year. On average, analysts predict that Pfizer will post $2.25 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Deutsche Bank initiated coverage on shares of Pfizer in a research note on Wednesday. They set a “buy” rating and a $34.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Pfizer in a research note on Friday, August 22nd. They now have a $30.00 price target on the stock. Finally, analysts at Credit Suisse cut their price target on shares of Pfizer from $35.00 to $34.00 in a research note on Thursday, August 14th.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Receive News & Ratings for Pfizer Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.